Study:
A Limited Access Phase II Trial of Cetuximab (C225, NSC #714692) in Combination With Cisplatin (NSC #119875) in the Treatment of Advanced, Persistent, or Recurrent Carcinoma of the Cervix
Rationale:
Monoclonal antibodies, such as cetuximab, can block tumor growth in different
ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and
help kill them or carry tumor-killing substances to them. Cetuximab may also help cisplatin
work better by making tumor cells more sensitive to the drug. Drugs used in chemotherapy,
such as cisplatin, work in different ways to stop the growth of tumor cells, either by
killing the cells or by stopping them from dividing. Giving cetuximab together with
cisplatin may be a better way to block tumor growth.
Purpose:
This phase II trial is studying how well giving cetuximab together with cisplatin
works in treating patients with advanced, persistent, or recurrent cervical cancer.
Study Status: Completed
Recruiting:
n/a
| Condition |
Intervention |
Phase |
|
Cervical Cancer |
Biological: cetuximab
Drug: cisplatin |
Phase 2 |
Verified by
Gynecologic Oncology Group
February, 2009
Sponsored by: Gynecologic Oncology Group
Information provided by: National Cancer Institute (NCI)
ClinicalTrials.gov identifier: NCT00101192
Study Type: Interventional
Study Design: Masking: Open Label, Primary Purpose: Treatment
Cleveland Clinic Taussig Cancer Center
Cleveland, Ohio 44195
United States
John H. Farley, MD., Study Chair
Russell J. Schilder, MD.,